Breast Cancer

Positive Herceptin data presented at San Antonio Breast Cancer Symposium

Published in Drug Week, January 19th, 2007

Genentech, Inc., (DNA) announced positive results from the second interim analysis of BCIRG 006, a phase III study evaluating Herceptin (Trastuzumab) plus chemotherapy in early-stage HER2-positive breast cancer, as well as a final analysis of TAnDEM, a phase III trial studying Herceptin plus the hormone therapy anastrozole in hormone receptor-positive, HER2-positive metastatic breast cancer.

In addition, data from 170 studies evaluating Herceptin-based treatment regimens in a variety of settings and disease stages, including preliminary phase II data of Herceptin in combination with Avastin (bevacizumab) in HER2-positive metastatic breast cancer, were presented at the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2007-01-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry